Embryo Gene Editing to Save Trillions in Genetic Disease Treatment Costs: Growing Calls for Clinical Entry and Redesigned Regulatory Pathways
Background
Global healthcare systems spend trillions of dollars annually treating genetic diseases caused by single-gene mutations, such as cystic fibrosis, Huntington's disease, and hemophilia. Existing somatic gene therapies are administered to patients after birth, facing limitations in fully restoring already damaged organs or tissues. Furthermore, the ultra-high drug pricing structure, often costing billions of won per single dose, imposes a massive burden on both patients and medical insurance finances. Moreover, there are clear blind spots where it is impossible to select normal embryos through preimplantation genetic diagnosis (PGD) and in vitro fertilization (IVF) alone, such as in cases of autosomal dominant diseases or when both parents carry homozygous mutations. Following the controversy over unethical human embryo editing in 2018, the international academic community recommended a strong moratorium on germline gene editing. However, as the precision of genome editing tools has improved dramatically since then, there is a growing consensus that rather than unconditionally blocking therapeutic embryo editing, it should be brought into a clear, institutionalized regulatory framework.
Key Findings
This study identifies that germline gene editing (GGE) has reached a decisive turning point, shifting the medical system from a focus on post-disease management to a fundamental pre-implantation prevention framework. Side effects caused by early CRISPR-Cas9, such as DNA double-strand breaks (DSB), off-target effects, and embryonic mosaicism, have largely come under control through next-generation precision genome editing technologies. This is because Base Editing (BE) and Prime Editing (PE) technologies induce single-base substitutions or precise insertions of specific sequences without completely cutting DNA strands, significantly reducing the risk of chromosomal deletions. The researchers also noted changes in public perception alongside technical maturity. There is a steady increase in public support for therapeutic embryo editing among patient families seeking to break the cycle of rare genetic diseases and among the general public. This illustrates a shift in perspective from concerns over eugenic genetic modification to a realistic assessment of it as a legitimate medical intervention for preventing fatal genetic diseases. Accordingly, specific policy directions have been proposed to move away from the past stance of total prohibition and to urgently establish clear clinical protocols and multinational regulatory approval pathways to verify safety and efficacy in stages.
Implications and Outlook
The institutionalization of therapeutic embryo gene editing has the potential to fundamentally change the expenditure structure of public health finances by blocking the intergenerational transmission of single-gene genetic diseases. Analysis suggests that normalizing severe rare diseases at the early stage of onset could achieve significant structural savings in terms of medical economics, rather than incurring astronomical lifelong treatment and care costs. However, significant scientific and ethical hurdles remain to be overcome before actual clinical implementation. If mosaicism, where not all cells in the embryo are uniformly edited, cannot be perfectly prevented, it is difficult to guarantee the normal development of the fetus. It is also pointed out that the risk of micro-variants arising during embryo editing being passed on to future generations cannot be determined without long-term follow-up observations. The issue of genetic inequality arising from differing bioethical regulations across countries and the high cost of procedures is also cited as a challenge for the international community to address. Between total prohibition and indiscriminate allowance, the success of future commercialization hinges on establishing a multinational surveillance system that applies strict safety standards limited to severe diseases.
Global healthcare systems spend trillions of dollars treating inherited diseases. Therapeutic germline gene editing has the potential to fundamentally shift medicine from treatment to prevention by genetically correcting the disease mutation at the embryo stage. Advances in precision genome editing and increased public support suggest that the field is ready for new clinical and regulatory pathways.
If preimplantation embryo gene editing technology establishes a clinical pathway, it offers a clear reproductive option for high-risk couples who both carry recessive genetic disease mutations, such as sickle cell anemia or cystic fibrosis, rendering normal embryo selection impossible. By replacing the causative mutation with a normal sequence at the zygote stage obtained through IVF, not only the child to be born but also their descendants will be completely free from the risk of genetic diseases. This represents a shift in the treatment paradigm from chronic management, which relied on lifelong expensive medication or organ transplants, to one-time fundamental prevention at the preimplantation stage. The pharmaceutical and biotech industries will also undergo a shift, expanding R&D investment—previously concentrated on post-onset therapeutics—toward the development of precision editing platforms at the embryonic stage and safety verification technologies.